Which asthma biologic is the most popular of them all? by Angus Liu Thursday, November 21, 2019 In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.
GSK's Nucala shows up Fasenra with rare disease data win by Angus Liu Wednesday, November 13, 2019 After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.
AstraZeneca's Fasenra nabs at-home auto-injector nod from FDA by Kyle Blankenship Friday, October 4, 2019 In its severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace that its drug was more convenient for patients. Not anymore.
FDA rejects AZ's COPD triplet Breztri by Angus Liu Tuesday, October 1, 2019 Hoping to revive the case, AstraZeneca said it will submit results from another phase 3 trial that weren't originally included in its application.
GSK's Nucala cuts asthma attacks in interim real-world data by Kyle Blankenship Monday, September 30, 2019 GlaxoSmithKline's Nucala has been on the prowl for a leg up in severe asthma. Could new real-world data work some magic for the drug?
AZ amps up respiratory battle with Breztri trial win by Kyle Blankenship Wednesday, August 28, 2019 AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?
GlaxoSmithKline's Nucala scores convenience boost by Carly Helfand Friday, June 7, 2019 GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer.
Novartis' Xolair eyes sinusitis to backstop blockbuster sales by Kyle Blankenship Tuesday, June 4, 2019 Facing stiff competition in asthma, Novartis’ Xolair can use all the help it can get to keep its blockbuster status. Could sinusitis be the cure?
AZ's Fasenra benefits hold up for 2 years: analysis by Eric Sagonowsky Monday, May 20, 2019 AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.
